Paris, FRANCE – December 5th 2023 – Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of...
Preeminent IP position gives Sherlock freedom to operate and commercialize across multiple CRISPR business avenues.
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease.
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines.
Eligo Bioscience announced today the issuance by the US Patent and Trademark Office of a landmark CRISPR patent that broadly covers any therapeutic...
Global genomics solutions provider Integrated DNA Technologies releases Alt-R HDR Donor Blocks, an improved solution for increasing homology-directed...
